Prolia RANKL Binding Assay

BioOutsource has extensive experience in the design, optimization, qualification and implementation of novel binding assays suitable for the assessment of a range of monoclonal antibody therapeutics.  This provides a strong basis for innovative solutions to the quantification, assessment and comparison of Prolia (Denosumab) binding assessments.  These binding assays are developed to characterize the primary action of Fab-associated binding affinity for RANKL.

Interaction studies are fundamental to understanding the function of monoclonal antibodies as therapeutic molecules.  RANKL binding assays can be performed using a number of different assay platforms, and each platform method can utilize different assay designs.  BioOutsource has developed the following Prolia (denosumab) Fab binding assays:

RANKL Binding by ELISA

BioOutsource offers a RANKL binding assay using a traditional ELISA platform. The relative binding of the biosimilar as a percentage of a designated reference standard lot is reported along with comprehensive parallelism assessments.  BioOutsource works closely with our clients to ensure the assay method meets the requirements of your study.

Contact our experts today to discuss your requirements.

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.